6/5
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
6/3
08:00 am
arqt
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
Low
Report
New Expert Consensus Provides Age-Specific Guidance for Improving Care for Individuals with Genital Psoriasis Published in the American Journal of Clinical Dermatology
5/26
04:00 pm
arqt
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
Low
Report
Arcutis Management to Present at Goldman Sachs 47th Annual Global Healthcare Conference
5/15
07:57 am
arqt
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound [Seeking Alpha]
Low
Report
Arcutis Biotherapeutics: The Dermatology Platform Is Starting To Compound [Seeking Alpha]
5/9
01:43 am
arqt
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics (ARQT) Is Down 11.0% After Strong Q1 And sNDA For ZORYVE Expansion [Yahoo! Finance]
5/8
04:47 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
5/8
04:00 pm
arqt
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
5/7
09:34 am
arqt
Arcutis (ARQT) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Arcutis (ARQT) Q1 2026 Earnings Transcript [Globe and Mail, The (Toronto, Canada)]
5/7
08:02 am
arqt
Arcutis Biotherapeutics (ARQT) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $36.00 price target on the stock.
Medium
Report
Arcutis Biotherapeutics (ARQT) had its "buy" rating reaffirmed by Needham & Company LLC. They now have a $36.00 price target on the stock.
5/7
12:43 am
arqt
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript [Seeking Alpha]
High
Report
Arcutis Biotherapeutics, Inc. (ARQT) Q1 2026 Earnings Call Transcript [Seeking Alpha]
5/6
07:13 pm
arqt
Arcutis Biotherapeutics Q1 Earnings Call Highlights [Yahoo! Finance]
High
Report
Arcutis Biotherapeutics Q1 Earnings Call Highlights [Yahoo! Finance]
5/6
04:51 pm
arqt
Arcutis Biotherapeutics GAAP EPS of -$0.09 in-line, revenue of $105.4M beats by $1.74M [Seeking Alpha]
High
Report
Arcutis Biotherapeutics GAAP EPS of -$0.09 in-line, revenue of $105.4M beats by $1.74M [Seeking Alpha]
5/6
04:00 pm
arqt
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
High
Report
Arcutis Announces First Quarter 2026 Financial Results and Provides Business Update
4/27
08:16 am
arqt
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months [Yahoo! Finance]
Low
Report
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months [Yahoo! Finance]
4/27
08:00 am
arqt
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
Low
Report
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months
4/24
08:07 pm
arqt
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves [Yahoo! Finance]
Low
Report
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves [Yahoo! Finance]
4/22
08:00 am
arqt
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
Low
Report
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines
4/19
12:02 pm
arqt
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants [Yahoo! Finance]
4/15
04:00 pm
arqt
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
Low
Report
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026
4/14
11:28 pm
arqt
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive [Yahoo! Finance]
Low
Report
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive [Yahoo! Finance]
4/8
04:27 pm
arqt
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? [Yahoo! Finance]
Low
Report
Is It Too Late To Revisit Arcutis Biotherapeutics (ARQT) After A 75% One-Year Surge? [Yahoo! Finance]
4/8
03:33 am
arqt
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets [Yahoo! Finance]
Low
Report
How The Arcutis Biotherapeutics (ARQT) Story Is Evolving As Analysts Cluster Around US$35 Targets [Yahoo! Finance]
3/31
04:00 pm
arqt
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
Low
Report
Arcutis Management to Present at the 25th Annual Needham Virtual Healthcare Conference
3/30
06:18 am
arqt
Arcutis Biotherapeutics (ARQT) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
Medium
Report
Arcutis Biotherapeutics (ARQT) had its "sell (d-)" rating reaffirmed by
Weiss Ratings.
3/28
11:47 am
arqt
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting [Yahoo! Finance]
Low
Report
Arcutis Presents New Phase 2 Results in Infants with Atopic Dermatitis in Late-Breaking Session Today at the 2026 American Academy of Dermatology Annual Meeting [Yahoo! Finance]